2011-08-30 02:35 (comments: 0)
Postmarketing safety data is significant even when there are no new signals identified. Pharmaceutical and biotechnology companies should develop a pharmacovigilance/drug safety system that can draw firm conclusions from spontaneous safety data and make the data publicly available. Doing so serves to increase market trust of the company as well as continue to "validate" the safety profile of a marketed product.
Read more … Postmarketing Safety Data Drives Significant Value Even in the Absence of Identified Signals
